keyword
MENU ▼
Read by QxMD icon Read
search

Bioresorbable scaffold

keyword
https://www.readbyqxmd.com/read/29149727/surface-modification-of-electrospun-poly-l-lactic-acid-scaffolds-by-reactive-magnetron-sputtering
#1
E N Bolbasov, P V Maryin, K S Stankevich, A I Kozelskaya, E V Shesterikov, Yu I Khodyrevskaya, M V Nasonova, D K Shishkova, Yu A Kudryavtseva, Y G Anissimov, S I Tverdokhlebov
In this study, we modified the surface of bioresorbable electrospun poly-(l-lactic) acid (PLLA) scaffolds by reactive magnetron sputtering of a titanium target under a nitrogen atmosphere. We examined the influence of the plasma treatment time on the structure and properties of electrospun PLLA scaffolds using SEM, XRF, FTIR, XRD, optical goniometry, and mechanical testing. It was observed that the coating formed did not change physicomechanical properties of electrospun PLLA scaffolds and simultaneously, increased their hydrophilicity...
November 12, 2017: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/29147473/bioresorbable-vascular-scaffold-versus-metallic-stent-in-percutaneous-coronary-intervention-results-of-the-aida-trial
#2
Syed Raza Shah, Mazia Fatima, Amin Muhammad Dharani, Waqas Shahnawaz, Syed Arbab Shah
Drug-eluting stents have significantly improved the long-term outcomes of percutaneous coronary intervention (PCI) by decreasing the excessive growth of neointima. However, conventional stents have some limitations. PCI with a bioresorbable vascular scaffold (BVS) has emerged as an alternative since the presence of the prosthesis in the coronary artery is transient. A US Food and Drug Administration advisory panel of experts recommended approval of BVS based on the analysis of its risks and rewards in July 2016...
2017: Journal of Community Hospital Internal Medicine Perspectives
https://www.readbyqxmd.com/read/29143226/aligned-ovine-diaphragmatic-myoblasts-overexpressing-human-connexin-43-seeded-on-poly-l-lactic-acid-scaffolds-for-potential-use-in-cardiac-regeneration
#3
Carlos Sebastián Giménez, Paola Locatelli, Florencia Montini Ballarin, Alejandro Orlowski, Ricardo A Dewey, Milagros Pena, Gustavo Abel Abraham, Ernesto Alejandro Aiello, María Del Rosario Bauzá, Luis Cuniberti, Fernanda Daniela Olea, Alberto Crottogini
Diaphragmatic myoblasts (DMs) are precursors of type-1 muscle cells displaying high exhaustion threshold on account that they contract and relax 20 times/min over a lifespan, making them potentially useful in cardiac regeneration strategies. Besides, it has been shown that biomaterials for stem cell delivery improve cell retention and viability in the target organ. In the present study, we aimed at developing a novel approach based on the use of poly (L-lactic acid) (PLLA) scaffolds seeded with DMs overexpressing connexin-43 (cx43), a gap junction protein that promotes inter-cell connectivity...
November 15, 2017: Cytotechnology
https://www.readbyqxmd.com/read/29137819/vascular-response-and-healing-profile-of-everolimus-eluting-bioresorbable-vascular-scaffolds-for-percutaneous-treatment-of-chronic-total-coronary-occlusions-a-one-year-optical-coherence-tomography-analysis-from-the-ghost-cto-registry
#4
Alessio La Manna, Eligio Miccichè, Guido D'Agosta, Gabriel Tensol Rodrigues Pereira, Guilherme Ferragut Attizzani, Piera Capranzano, Davide Capodanno, Corrado Tamburino
BACKGROUND: Bioresorbable vascular scaffolds (BVS) have been heralded with potential benefits that are especially desired in long lesions, including chronic total occlusions (CTOs). Procedural feasibility and mid-term outcomes of BVS in CTOs have been reported. However, there is still a paucity of data regarding the vascular and healing response to BVS in CTOs evaluated by optical coherence tomography (OCT). METHODS: This study included prospectively 21 patients who had a CTO lesion treated with a BVS...
November 8, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29131802/acute-and-one-year-clinical-outcomes-following-implantation-of-bioresorbable-vascular-scaffolds-the-absorb-uk-registry
#5
Andreas Baumbach, Azfar Zaman, Nick Ej West, Peter O'Kane, Mohaned Egred, Thomas Johnson, Stephen Wheatcroft, Bowles Ruth, Adam de Belder, Georgious Bouras, Alexandra Lansky, Jonathan Hill, Anthony Mathur, Mark A de Belder, Adrian Banning
AIMS: The aim was to monitor practice patterns and outcomes in patients treated with Absorb bioresorbable vascular scaffolds (BVS) during the early phase of usage in the UK. METHODS AND RESULTS: A total of 1005 patients with de-novo coronary lesions were treated using careful implantation techniques at 24 centers. Follow-up at one year was obtained in 99%. An independent clinical event committee and angiographic corelab adjudicated all events. Patient age was 52 years and 46% presented with acute coronary syndromes...
November 14, 2017: EuroIntervention
https://www.readbyqxmd.com/read/29131799/multi-slice-computed-tomography-assessment-of-everolimus-eluting-absorb-bioresorbable-scaffold-in-comparison-with-metallic-drug-eluting-stents-from-the-absorb-japan-randomized-trial
#6
Kengo Tanabe, Jeffrey J Popma, Ken Kozuma, Shigeru Saito, Toshiya Muramatsu, Sunao Nakamura, Atsuo Namiki, Yoshihiro Morino, Nobuhisa Hagiwara, Masaaki Uematsu, Tomohiro Kawasaki, Kenshi Fujii, Patrick W Serruys, Yoshinobu Onuma, Shihwa Ying, Hajime Kusano, Gregg W Stone, Takeshi Kimura
AIMS: Blooming artifacts limit accurate coronary assessment by multi-slice computed tomography (MSCT) in metallic stents. We sought to investigate whether bioresorbable vascular scaffold (BVS) could be better assessed by MSCT. Methods and Results: Among 400 patients in the randomized ABSORB Japan trial, a pre-specified MSCT sub-study was performed in 98 patients (103 lesions) in the BVS arm and 49 patients (49 lesions) in the cobalt chromium everolimus-eluting stent (CoCr-EES) arm at 13-month prior to follow-up angiography...
November 14, 2017: EuroIntervention
https://www.readbyqxmd.com/read/29126043/biphasic-bioresorbable-scaffold-trufit-plug-%C3%A2-for-the-treatment-of-osteochondral-lesions-of-talus-6-to-8-year-follow-up
#7
Elvira Di Cave, Pierluigi Versari, Fabio Sciarretta, David Luzon, Lorenzo Marcellini
BACKGROUND: The ideal treatment of osteochondral lesions of the talus (OLT) is debatable. The TruFit plug has been investigated as a potential treatment method for osteochondral defects. This is a biphasic scaffold designed to stimulate cartilage and subchondral bone formation. The purpose of this retrospective study was to investigate the long-term functional and MRI outcomes of the TruFit Plug for the treatment of OLT. METHODS: Twelve consecutive patients treated from March 2007 to April 2009 for OLT were evaluated...
June 3, 2017: Foot
https://www.readbyqxmd.com/read/29108400/early-experience-and-favorable-clinical-outcomes-of-everolimus-eluting-bioresorbable-scaffolds-for-coronary-artery-disease-in-korea
#8
Osung Kwon, Jung-Min Ahn, Do-Yoon Kang, Se Hun Kang, Pil Hyung Lee, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Duk-Woo Park, Seung-Jung Park
Background/Aims: Compared with metallic drug-eluting stents (DES), bioresorbable vascular scaffolds (BVS) may further improve long-term outcomes of percutaneous coronary intervention (PCI) in patients with coronary artery disease. We report our early experience with BVS in Korea. Methods: We evaluated 105 consecutive patients with BVS implanted at Asan Medical Center, Korea between October 21, 2015 and June 3, 2016. Angiographic results, and in-hospital and 6-month clinical outcomes were assessed...
November 7, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29104780/induction-of-icam-1-expression-in-mouse-embryonic-fibroblasts-cultured-on-fibroin-gelatin-scaffolds
#9
M A Nosenko, N V Maluchenko, M S Drutskaya, A Y Arkhipova, I I Agapov, S A Nedospasov, M M Moisenovich
Culturing of allogeneic or autologous cells in three-dimensional bioresorbable scaffolds is an important step in the engineering of constructs for regenerative medicine, as well as for experimental systems to study the mechanisms of cell differentiation and cell-to-cell interaction. Artificial substrates can modulate the phenotype and functional activity of immobilized cells. Investigating these changes is important for understanding the fundamental processes underlying cellular interactions in a 3D microenvironment and for improving tissue-engineered structures...
July 2017: Acta Naturae
https://www.readbyqxmd.com/read/29100704/effect-of-technique-on-outcomes-following-bioresorbable-vascular-scaffold%C3%A2-implantation-analysis-from-the-absorb-trials
#10
Gregg W Stone, Alexandre Abizaid, Yoshinobu Onuma, Ashok Seth, Runlin Gao, John Ormiston, Takeshi Kimura, Bernard Chevalier, Ori Ben-Yehuda, Ovidiu Dressler, Tom McAndrew, Stephen G Ellis, Dean J Kereiakes, Patrick W Serruys
BACKGROUND: Procedural technique may affect clinical outcomes after bioresorbable vascular scaffold (BVS) implantation. Prior studies suggesting such a relationship have not adjusted for baseline patient and lesion characteristics that may have influenced operator choice of technique and outcomes. OBJECTIVES: This study sought to determine whether target lesion failure (TLF) (cardiac death, target-vessel myocardial infarction, or ischemia-driven target lesion revascularization) and scaffold thrombosis (ScT) rates within 3 years of BVS implantation are affected by operator technique (vessel size selection and pre- and post-dilation parameters)...
October 20, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29100702/3-year-clinical-outcomes-with-everolimus-eluting-bioresorbable-coronary-scaffolds-the%C3%A2-absorb-iii-trial
#11
Dean J Kereiakes, Stephen G Ellis, Christopher Metzger, Ronald P Caputo, David G Rizik, Paul S Teirstein, Marc R Litt, Annapoorna Kini, Ameer Kabour, Steven O Marx, Jeffrey J Popma, Robert McGreevy, Zhen Zhang, Charles Simonton, Gregg W Stone
BACKGROUND: The Absorb everolimus-eluting poly-L-lactic acid-based bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support functions similar to metallic drug-eluting stents (DES), followed by complete bioresorption in approximately 3 years with recovery of vascular structure and function. The ABSORB III trial demonstrated noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction [TVMI], or ischemia-driven target lesion revascularization) at 1 year in 2,008 patients with coronary artery disease randomized to BVS versus cobalt-chromium everolimus-eluting stents (EES)...
October 20, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29096803/mechanisms-of-very-late-bioresorbable%C3%A2-scaffold-thrombosis-the-invest-registry
#12
Kyohei Yamaji, Yasushi Ueki, Geraud Souteyrand, Joost Daemen, Jens Wiebe, Holger Nef, Tom Adriaenssens, Joshua P Loh, Benoit Lattuca, Joanna J Wykrzykowska, Josep Gomez-Lara, Leo Timmers, Pascal Motreff, Petra Hoppmann, Mohamed Abdel-Wahab, Robert A Byrne, Felix Meincke, Niklas Boeder, Benjamin Honton, Crochan J O'Sullivan, Alfonso Ielasi, Nicolas Delarche, Günter Christ, Joe K T Lee, Michael Lee, Nicolas Amabile, Alexios Karagiannis, Stephan Windecker, Lorenz Räber
BACKGROUND: Very late scaffold thrombosis (VLScT) occurs more frequently after bioresorbable scaffold (Absorb BVS 1.1, Abbott Vascular, Santa Clara, California) implantation than with metallic everolimus-eluting stents. OBJECTIVES: The purpose of this study was to elucidate mechanisms underlying VLScT as assessed by optical coherence tomography (OCT). METHODS: The INVEST (Independent OCT Registry on Very Late Bioresorbable Scaffold Thrombosis) registry is an international consortium of investigators who used OCT to examine patients with VLScT...
November 7, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29094677/four-year-follow-up-of-the-randomised-comparison-between-an-everolimus-eluting-bioresorbable-scaffold-and-an-everolimus-eluting-metallic-stent-for-the-treatment-of-coronary-artery-stenosis-absorb-ii-trial
#13
Bernard Chevalier, Angel Cequier, Dariusz Dudek, Michael Haude, Didier Carrie, Manel Sabaté, Stephan Windecker, Sebastian Reith, Manuel de Sousa Almeida, Gianluca Campo, Andres Iñiguez, Yoshi Onuma, Patrick W Serruys
AIMS: No randomised comparison data are available beyond the resorption of the everolimus-eluting bioresorbable scaffold. Absorb is expected to be completely resorbed by 3 years. The purpose of this report is to provide the 4 year results of a randomised, single blind, multicentre evaluation of Absorb versus the metallic stent Xience (Abbott Vascular, Santa Clara, CA, USA). METHODS AND RESULTS: Three-year follow-up has been previously published. Patients re-consented for additional follow-up up through to 5 years; 86% (N=289) and 84% (N=139) of whom underwent a 4 year follow-up visit...
October 31, 2017: EuroIntervention
https://www.readbyqxmd.com/read/29091563/bioresorbable-scaffolds-versus-metallic-stents-in-routine-pci
#14
LETTER
Robin P Kraak, Joanna J Wykrzykowska
New England Journal of Medicine, Volume 377, Issue 18, Page 1790-1792, November 2017.
November 2, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29089314/three-year-outcomes-with-the-absorb-bioresorbable-scaffold-individual-patient-data-meta-analysis-from-the-absorb-randomized-trials
#15
Ziad A Ali, Runlin F Gao, Takeshi Kimura, Yoshinobu Onuma, Dean J Kereiakes, Stephen G Ellis, Bernard Chevalier, Minh-Thien Vu, Zhen Zhang, Charles A Simonton, Patrick W Serruys, Gregg W Stone
BACKGROUND : The Absorb bioresorbable vascular scaffold (BVS) completely resorbs within 3 years after coronary artery implantation. The safety and effectiveness of BVS through this critical 3-year period have not been characterized. METHODS : We performed an individual-patient-data pooled meta-analysis of the 4 randomized ABSORB trials in which 3389 patients with coronary artery disease were randomly assigned to everolimus-eluting Absorb BVS (n=2164) or cobalt-chromium everolimus-eluting stents (n=1225). The primary efficacy outcome measure was target lesion failure (cardiac mortality, target vessel myocardial infarction, or ischemia-driven target lesion revascularization), and the primary safety outcome measure was device thrombosis...
October 31, 2017: Circulation
https://www.readbyqxmd.com/read/29081013/emerging-technologies-in-flow-diverters-and-stents-for-cerebrovascular-diseases
#16
REVIEW
Michael Karsy, Jian Guan, Andrea A Brock, Anubhav Amin, Min S Park
PURPOSE OF REVIEW: Stents and flow diverters have revolutionized the treatment of cerebrovascular disease. Guglielmi coils, flexible microcatheters, and first-generation intracranial stents, such as Neuroform (Stryker Neurovascular) and Enterprise stents (Codman/DePuy-Synthes), have paved the way for the development of the Pipeline Embolization Device (PED) (ev3/Covidien/Medtronic) and other endovascular approaches. RECENT FINDINGS: This review discusses the historical development of flow diverter technologies from the PED to similar devices, such as the Surpass stent (Stryker Neurovascular), the Flow-Redirection Endoluminal Device (FRED; MicroVention, Inc...
October 28, 2017: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/29076827/one-year-imaging-follow-up-of-a-self-expanding-bifurcation-drug-eluting-stent-and-bioresorbable-scaffold-for-a-complex-bifurcation-lesion
#17
Akihiro Nakajima, Hiroyoshi Kawamoto, Sunao Nakamura, Damras Tresukosol
No abstract text is available yet for this article.
October 25, 2017: Coronary Artery Disease
https://www.readbyqxmd.com/read/29068171/one-year-clinical-and-computed-tomography-follow-up-after-implantation-of-bioresorbable-vascular-scaffolds-in-patients-with-coronary-chronic-total-occlusions
#18
Joren Maeremans, David Verhaert, Bruno Pereira, Peter Frambach, Carlos Van Mieghem, Emanuele Barbato, Endry Willems, Mathias Vrolix, Jo Dens
OBJECTIVES: To assess the safety and efficacy of everolimus-eluting bioresorbable scaffolds (BRS) in the treatment of chronic total occlusions (CTO) using noninvasive multislice computed tomography (MSCT) angiography at one-year follow-up. BACKGROUND: Current evidence regarding the safety and efficacy of BRS for the percutaneous treatment of CTO is limited. METHODS: Between September 2013 and January 2016, patients who received one or more ABSORB BRSs were included at three centers...
October 25, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29068130/clinical-outcomes-of-patients-with-diabetes-mellitus-treated-with-absorb-bioresorbable-vascular-scaffolds-a-subanalysis-of-the-european-multicentre-ghost-eu-registry
#19
Piera Capranzano, Davide Capodanno, Salvatore Brugaletta, Azeem Latib, Julinda Mehilli, Holger Nef, Tommaso Gori, Maciej Lesiak, Salvatore Geraci, Stelios Pyxaras, Alessio Mattesini, Thomas Münzel, Aleksander Araszkiewicz, Giuseppe Caramanno, Christoph Naber, Carlo Di Mario, Manel Sabatè, Antonio Colombo, Jens Wiebe, Corrado Tamburino
BACKGROUND: Data on the clinical performance of bioresorbable scaffolds in patients with diabetes mellitus (DM) are still limited. The present study reported 1-year clinical outcomes associated with the use of everolimus-eluting bioresorbable vascular scaffolds (Absorb BVS; Abbott Vascular, Santa Clara, CA) in DM patients. METHODS AND RESULTS: This was a subanalysis from the GHOST-EU (Gauging coronary Healing with biOresorbable Scaffolding plaTforms in Europe) multicenter retrospective registry including patients treated with Absorb BVS between November 2011 and September 2014...
October 25, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29066339/long-term-invasive-follow-up-of-bioresorbable-vascular-scaffold-optical-coherence-tomography-assessment-of-jailed-side-branches
#20
Valeria Paradies, Pieter C Smits, Georgios J Vachojannis, Kees-Jan Royaards, Jochem Wassing, Martin van der Ent
BACKGROUND: Little is known about the long term development of the tissue bridges covering the struts of bioresorbable vascular scaffold (BVS) at the side branches (SB) ostium. This study aims at assessing the resorption process of jailed SB after BVS implantation. METHODS: We performed both Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) analysis of 7 patients enrolled in the ABSORB Cohort B trial at our center. Orifice SB area and mean thickness of tissue bridge covering SB were calculated from 2D assessment...
September 10, 2017: Cardiovascular Revascularization Medicine: Including Molecular Interventions
keyword
keyword
52455
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"